Myocardial Infarction Obesity Preserved Ejection Fraction 
Cardiometabolic Health Congress
JULY 25, 2023
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
DAIC
FEBRUARY 29, 2024
ET Main Tent (Hall B1) - A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial - Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial - CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients (..)
Cardiology Update
APRIL 9, 2024
EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. in the medical therapy group.
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2025
BackgroundThe mortality of patients with acute myocardial infarction (MI) raised rapidly in last decade and obesity are becoming the major cause to CAD progression, thus inducing heart failure preserved ejection fraction (HFpEF). Also, SASPs decreased in hypoxic fibroblasts after OGN knockdown.
Cardiometabolic Health Congress
NOVEMBER 14, 2024
42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Emerging Risk Factors: Non-traditional factors such as the microbiome, pollution, and somatic mutations are increasingly linked to “SMuRFless” myocardial infarction (MI) cases. In the U.S.,
Expert insights. Personalized for you.
52 
Let's personalize your content